Member Info for ABftse

So Valirx is getting $4 and $8 million in grants? What a load of tripe.

The lab opened nearly 3 years ago - to generate revenue - revenues are non existent.

The Marker Makers must be worried ... halving the spread to 7.14% ... tells you everything.

So many on here averaging down - why average down when you could just sell?

So many hold and hopers on here. Very sad.

No, I'm not looking to "get in at a cheap price". The assets are not even worth £40k let alone £1.9 million.

Porky is right, this seems like a part-time job for those working here. Revenue zero or miniscule. No new projects and no money for them. What could they be doing all day? Waiting for the next discounted placing in 3-4 months. Shambles.

Adam Hargreaves sold his Valirx shares and moved to Aptamer Group (he is non-exec chair there).

Adam is a great guy, always very professional, and helped Valirx a lot. He never got the thanks he deserved though.

The end of Valirx is near IMO.

Around previous fundraising, the former CEO, Suzy Dilly, would hold webinars talking about the next big thing. TheoremRX. VAL201. The Letter of Intent. The money was just around the corner. But after years of no progress from TheoremRx, shareholders were losing patience. To reassure investors, Suzy Dilly updated her Twitter profile to say: "Confident and Unconcerned" (or words to that effect). She was confident and unconcerned a deal from TheoremRx was coming by "year end". Apparently, they were in "continued discussions with ThoeremRx".

But nothing materialised. And the share price dropped by 99%.

Shareholders felt mislead. Apparently, Suzy Dilly now works at University of Cambridge. (She is very lucky to get that gig.)

And still, there is no revenue today. Nothing interesting at all. £2.05 million market cap for Valirx is too much. Even the lab has done practically no revenue. If they cannot sell a service in their own lab - how can they commercialise any of the pipeline?

Unless this can be pumped all the way to 0.25, I would expect this to fall further. The market cap is not even worth £1 million in IMO let alone £2 million. Maybe 0.05 is a fair price?

( viera - get out while you still can !!! )

Maybe the BDM gets the placing through ... but for how much longer?

There's no innovation here. The lab has practically zero revenue which is frankly ridiculous. Why has it gone so wrong?

The market cap actually seems expensive for this business.

This doesn't seem or feel like previous placings. This time it seems like the price will fall further.

So many better opportunities out there.

I'm surprised Val has managed to go from 0.23 to 0.43 on nothing more than hot air.

Rerate back down to 0.25-0.30 is coming very soon.

Smart money is leaving already. Unless you are deluded it is time to sell.

On 18 Oct '25, I said: "Placement imminent IMO. Placing likely to be around 0.10-0.20."

What will happen in 5 months time, Oldbaldy?

They either reduce staffing costs and bring in revenue or another highly discounted placing.

They could have had Adam on the board a few years ago but they rejected that. If they had intergrated his (sucessfull) business, then they could of had a business which turns over MORE THAN £31,000 pounds per year.

And to think Suzy Dilly former CEO was on over £180,000 pa.

Disgrace.

Adam was a big shareholder here and a true great guy. Maybe he is still a shareholder, I don't know. He helped the board as much as he could, even giving up his time for free. The board continue to pay large salaries with very little revenue.

My 18 October 2025 prediction came true, unfortunately:

"There is a placement imminent IMO.

Placing likely to be around 0.10-0.20 - that's IF THEY GET SUPPORT FOR A PLACING. If not, then they are likely to enter admin.

Revenue of £31,000 is a joke.

High costs.

So many have been let down here."

----------

So what needs to happen now? Either sell the lab or make it profitable.

There is a placement imminent IMO.

Placing likely to be around 0.10-0.20 - that's IF THEY GET SUPPORT FOR A PLACING. If not, then they are likely to enter admin.

Revenue of £31,000 is a joke.

High costs.

So many have been let down here.

Wondering what placing discount this will be ? 0.20?

Good to hear from you. You were retiring to Greece, I remember.

There was more chat on this board in the old days.

I can see Val price going lower - around 0.20 - before we head up. If this placing is around the corner, then I can expect a huge discount, as is the way.

I sold out in 2023 with a x4 profit.

Been watching this for a while with no stake. Now I am back in looking for similar, ideally x8 profit. I can see this going to 0.85 in the short term based on news on CLX in San Diego.

These boards are not conveying the changes that have happened at Val. It is now under valued in my opinion. Val has turned around.

I can see this going to 0.85 based on positive news from San Diego.

How is oldbaldy, is he still around?

Let's go!

Agreed. This is good for Valirx.

I sold out in 2023 with a x4 profit.

Now I am back in looking for similar, ideally x8 profit. I can see this going to 0.85 in the short term based on news on CLX in San Diego.

There's still the negativity on these boards. Some historic negativity was fair, but Val has turned around.

Val has been always one to have big increases on positive news as we've seen before.

So, short term prediction 0.50 to 0.85.

My target is x8 times profit.

Lets go!

Well said Fred

Easy doubler !

New contracts for tCRO, Kings update, so much news to come!

tCRO showing signs of success at this early stage.

At these prices, any small number of buys would result in 10%, 20% increases . . .not to be missed. Maybe metom reinvest.

The new contract is the start of many.

Have a great weekend everyone.

First-ever revenue in the company's history.

£20 million revenue targets by 2027.

Great news - first ever revenue !

Good one OB. Spot on!

Metom this is totally the wrong time to be selling. Price will double on decent news (which we've not had much of recently).

It was savvy business to purchase Imagen Therapeutics' assets for almost nothing. They have the co-founder of Imagen on their staff, so they only need to keep working with their clientele. The new Inaphaea lab is already home to Imagen Therapeutics assets. Revenue this quarter is anticipated. They are already in discussions or negotiations with potential customers, so if a contract is signed and announced, stock prices should rise by double digits.

Everything is OK (even if the share price isn't). Our price would be 10 times greater if we were listed on Nasdaq.